Producer Cell Line Development for Viral Vectors & Vaccines

Get the right cell line for production of your vector and virus!

At ProBioGen, we understand that viral vector manufacturing is not a one-size-fits-all solution. Whether you are in early-stage R&D, scaling up for clinical trials, or preparing for commercial production, choosing the right approach is critical for cost-efficiency, scalability, and regulatory success. With more than 30 years of expertise in cell line development (CLD) and viral vector production, we offer tailored solutions designed to meet your specific needs.

We combine decades of experience in CLD with cutting-edge technologies to deliver tailored solutions for viral vector and virus production. Our flexible approach covers the full product lifecycle – from transient transfection for early-stage agility to high-titer pooled producer cell lines to bridge the gap to stable systems to packaging cell lines for efficient transgene integration to custom-designed stable producer cell lines for scalable manufacturing. We provide a seamless, de-risked path from R&D to GMP production to accelerate your time to clinic.

The Ideal Cell Line

At our facility, we have generated several specialized cell lines to meet diverse production needs. Most notably, we have developed a proprietary GMP-compliant HEK293 cell line optimized for growth in chemically defined medium in suspension.

Our HEK293 cell line is specifically engineered for the production of lentiviruses, AAV, and adenoviruses. This cell line offers unparalleled control over the manufacturing process, ensuring consistency and quality in the final product.

Transposase for Cell Engineering

DirectedLuck^® facilitates gene delivery based on epigenetic targeting and carefully designed transposase and transposons. Our technology delivers transposons specifically to integration sites with the highest transcriptional activity.

Easy adjustment of gene dosage facilitates a concerted expression of viral components and target genes. This results in elevated titers and outstanding stability of the robust packaging/producer cell lines we create for our clients. DirectedLuck^®enables highly efficient and scalable production of viral vectors while speeding time to clinic.

The Right Strategy Tailored to Your Therapy

Every therapy has unique requirements, and one size does not fit all in viral vector production. We work closely with our clients to define the best approach - whether that is a packaging cell line with transgene flexibility, a full producer cell line, or an optimized transient-based workflow. Our deep expertise in cell line engineering, process development, and GMP manufacturing ensures a smooth transition from R&D to commercial production.

Viral vector production requires both scientific precision and real-world manufacturing expertise. We combine decades of cell line development know-how with a pragmatic approach - offering solutions that are scalable, cost-effective, and regulatory-compliant. Whether you want to evaluate use of a stable production system with producer pools or seek custom development of a commercial-ready producer cell line, our strategies ensure a rapid and smooth path to scalable manufacturing.

Precision Engineering Meets Smart Automation

Our proprietary transposase technology, DirectedLuck^®, facilitates multi-gene integration at highly active genomic sites, enabling optimal expression of viral genes. In combination with our inducible gene expression system, this provides tight control, preventing unwanted effects and ensuring high-titer viral vector production.

After transfection, we ensure that only the best-performing and most suitable clones move forward by leveraging our high-throughput screening and automated clone selection process. During the whole CLD process, we reduce timelines and enhance reproducibility by implementing automation in transfection, screening, and stability assessments.

Bulk Pools Ready for Manufacturing – A New Approach to Stable Lentiviral Production

Traditional stable cell line development can take up to 9 months - our pooled producer cell lines accelerate the timeline significantly. Using our proprietary screening and selection technologies, we generate bulk producer pools with high titers in just 6 - 8 weeks. This approach eliminates the need for full clone selection in the beginning of the project, reducing risk while ensuring manufacturability from an early stage. Thereby, customers can evaluate the use of stable production systems in a fast and affordable way. Ideal for companies looking for a cost-effective, scalable solution without the need to directly commit to a fully stable producer line.

GMP-Ready and Built for Scale from the Start

Scalability is built into our viral vector production strategies from day one. All of our cell lines are developed for suspension growth in chemically defined medium, ensuring seamless scale-up from R&D to commercial bioreactors. Our processes follow GMP guidelines, enabling a fast and efficient transition into clinical and commercial production. As a CDMO with more than 30 years of expertise, we don’t just develop your cell lines - we ensure they integrate seamlessly into full-scale manufacturing by offering end-to-end solutions. From cell line engineering and process development to GMP-compliant viral vector production, our high-performance cell lines can be used all the way from early development through commercial manufacturing, ensuring an efficient path from lab bench to clinic to market.

HEK293 Cell Line for Unparalleled Control

Duck Cell Line for the Production of MVA and Other Vaccine Candidates

Chemically Defined Media to Eliminate Variability

Consistency with Chemically Defined Medium

Rapid, Phase-Ready Delivery Without Compromise

Our modular platform enables flexible entry points - from transient transfection to full stable producer cell lines
Bulk pools deliver clinical-grade material with high titers in 6-8 weeks
By pairing high-throughput clone screening with integrated analytics, we accelerate development timelines without compromising quality